Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other financing activities (2019 - 2023)

Beam Therapeutics (BEAM) has disclosed Other financing activities for 5 consecutive years, with $384000.0 as the latest value for Q3 2023.

  • Quarterly Other financing activities rose 1436.0% to $384000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $631000.0 through Dec 2023, up 235.64% year-over-year, with the annual reading at $631000.0 for FY2023, 235.64% up from the prior year.
  • Other financing activities for Q3 2023 was $384000.0 at Beam Therapeutics, up from $185000.0 in the prior quarter.
  • The five-year high for Other financing activities was $8.0 million in Q1 2021, with the low at $6000.0 in Q1 2022.
  • Average Other financing activities over 5 years is $832176.5, with a median of $209000.0 recorded in 2021.
  • The sharpest move saw Other financing activities plummeted 99.92% in 2022, then surged 1436.0% in 2023.
  • Over 5 years, Other financing activities stood at $1.4 million in 2019, then crashed by 76.13% to $342000.0 in 2020, then crashed by 62.57% to $128000.0 in 2021, then plummeted by 57.81% to $54000.0 in 2022, then skyrocketed by 611.11% to $384000.0 in 2023.
  • According to Business Quant data, Other financing activities over the past three periods came in at $384000.0, $185000.0, and $62000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.